Brought to you by 
Hanmi partners again in diabetes with Big Pharma; this time J&J; Deal Terminated
04 Aug 2020
Executive Summary
Just days after announcing a potential $4.2bn diabetes licensing agreement with Sanofi, Hanmi Pharmaceutical Co. Ltd. inked another separate deal worth up to $915mm with Johnson & Johnson's Janssen Pharmaceuticals Inc. for Hanmi's diabetes and obesity candidate HM12525A, a long-acting glucagon-like peptide-1 (GLP-1)/glucagon (GCG) analog.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
-
Drug Delivery
-
Biotechnology
- Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Hanmi partners again in diabetes with Big Pharma; this time J&J; Deal Terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice